CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
sodium fluorescein injection 10%drug
Likely dose
Sodium fluorescein injection 10%AI-extracted
Key inclusion· 1
  • ✓Undergoing total laparoscopic hysterectomy
Key exclusion· 4
  • ✕Currently breastfeeding
  • ✕Renal insufficiency
  • ✕Taking Probenecid, digoxin, quinidine, or beta-blockers
  • ✕Hypersensitivity or intolerance to sodium fluorescein

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02971800
NCT02971800N/ACompleted
CompareCT.gov

Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy

CHU de Quebec-Universite Laval·interventional·Posted Nov 23, 2016·Updated Apr 1, 2021

In Brief

A clinical study evaluating sodium fluorescein injection 10% for Ureteral Injury. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The primary objective is to describe the safety and efficacy of intravenous sodium fluorescein to visualize ureteral efflux during intraoperative cystoscopy after total laparoscopic hysterectomy. Secondary objective is to report on surgeon's satisfaction with the overall use of sodium fluorescein.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUreteral Injury
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 23, 2016
Enrollment StartAug 1, 2016
Primary CompletionJan 1, 2017
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.6 years ago

Interventions

sodium fluorescein injection 10%drug